StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)

Analysts at StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the medical technology company’s stock.

Other analysts have also recently issued reports about the company. Ascendiant Capital Markets decreased their price objective on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. Benchmark reiterated a “speculative buy” rating and issued a $0.40 price objective on shares of BIOLASE in a research report on Wednesday, October 2nd.

BIOLASE Stock Performance

NASDAQ BIOL opened at $0.01 on Friday. BIOLASE has a one year low of $0.02 and a one year high of $1.94. The firm has a market cap of $250,552.50, a PE ratio of 0.00 and a beta of 0.67. The firm’s fifty day moving average is $0.01 and its two-hundred day moving average is $0.05.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.